HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

bimosiamose disodium

selectin inhibitor; structure in first source

Also Known As:

TBC 1269; TBC-1269

Networked: 9 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Benzene Derivatives: 17
        Biphenyl Compounds: 7
        bimosiamose disodium: 9
Carbohydrates: 22023
- Sugars: 11126
  - Monosaccharides: 889
    - Hexoses: 549
      - Mannose: 1927
        bimosiamose disodium: 9

Experts

1.	Toledo-Pereyra, Luis H: 4 articles (09/2008 - 05/2002)
2.	Anaya-Prado, Roberto: 2 articles (09/2008 - 05/2002)
3.	Ward, Peter A: 2 articles (09/2008 - 05/2002)
4.	Rabb, H: 2 articles (05/2006 - 12/2001)
5.	Jordan, Jackie: 1 article (09/2008)
6.	Pérez-Gomez, Nahum: 1 article (09/2008)
7.	Walsh, John: 1 article (09/2008)
8.	López-Neblina, Fernando: 1 article (04/2007)
9.	Calvey, Colleen R: 1 article (03/2007)
10.	Deretz, S: 1 article (05/2006)

Related Diseases

1.	Ischemia 12/01/2001 - "In rats with severe IRI, TBC-1269 treatment during IRI significantly reduced mortality at 48 hours post-ischemia. " 04/01/2007 - "Mice subjected to 90 min of partial (70-80%) hepatic ischemia and 3 h of reperfusion were divided into eight groups (n=6/group): sham, ischemic control (IC), three groups of TBC-1269-treated animals at different concentrations (10, 20, 40, mg/kg) and another three groups of TBC-1269 given at 40 mg/kg at different times of administration: 15 min prereperfusion but after ischemia (no pretreatment), at the time of reperfusion, and at 15 min after reperfusion. " 12/01/2001 - "Rats treated with TBC-1269 during moderate IRI showed significantly reduced serum creatinine (SCr) and tubular necrosis post-ischemia compared to control animals. " 04/01/2007 - "Preliminary studies in our laboratories indicate that a recently discovered synthetic drug, TBC-1269, acts as a multiple selectin blocker and provides protection against tissue damage in rats that are subjected to severe liver ischemia/reperfusion. "
2.	Psoriasis (Pustulosis Palmaris et Plantaris) 03/01/2007 - "Furthermore, TBC-1269 has recently undergone successful phase I and phase IIa clinical trials for asthma and psoriasis. " 01/01/2005 - "TBC-1269 (Bimosiamose), a structural mimetic of natural selectin ligands, inhibits P-, E-, and L-selectin in vitro, has anti-inflammatory effects in vivo, and recently underwent phase II clinical trials for childhood asthma and psoriasis. "
3.	Asthma (Bronchial Asthma) 03/01/2007 - "Furthermore, TBC-1269 has recently undergone successful phase I and phase IIa clinical trials for asthma and psoriasis. " 01/01/2005 - "TBC-1269 (Bimosiamose), a structural mimetic of natural selectin ligands, inhibits P-, E-, and L-selectin in vitro, has anti-inflammatory effects in vivo, and recently underwent phase II clinical trials for childhood asthma and psoriasis. "
4.	Shock 05/01/2002 - "Six groups of animals were included in this study (n = 16 per group): sham/saline, sham/LPS, shock/saline, shock/LPS, shock/TBC1269, and shock/TBC-1269/LPS. "
5.	Respiratory Syncytial Virus Infections 02/01/2003 - "The carbohydrate-based selectin antagonists, fucoidan and TBC 1269, inhibit RSV infection both in vitro and in a mouse model of infection. "

Related Drugs and Biologics

1.	Selectins
2.	Synthetic Drugs
3.	salicylhydroxamic acid (SHAM)
4.	L-Selectin
5.	Ligands
6.	bimosiamose
7.	E-Selectin
8.	P-Selectin
9.	Creatinine
10.	Carbohydrates

Related Therapies and Procedures

1.	Cardiopulmonary Bypass (Heart-Lung Bypass)